24 November 2021
EMA/584437/2021
EMEA/H/C/005181

Public statement

Equidacent

Withdrawal of the marketing authorisation in the European Union

On 23 September 2021, the European Commission withdrew the marketing authorisation for Equidacent (bevacizumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Centus Biotherapeutics Europe Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Equidacent was granted marketing authorisation in the EU on 24 September 2020 for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer, first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer, and first line treatment of patients with advanced and/or metastatic renal cell cancer. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU.

The European Public Assessment Report (EPAR) for Equidacent will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union